Triastek is a Nanjing-based pharmaceutical technology company and a global leader in 3D-printed pharmaceuticals, using its proprietary Melt Extrusion Deposition (MED) platform to design and continuously manufacture novel oral drug products. It is the only company in China holding a production license for 3D-printed drugs and has secured multiple FDA IND clearances. Its newer strategic focus is oral peptides, delivered via its 3DuS-OM platform, with a Shanghai international R&D and production center supporting clinical and global commercialization.
1
Round
1
Industry
5
Tags
Oct 9, 2026
Latest raise
Funding activity · 1 round
Oct 9, 2026
Series C+
Led by Johnson & Johnson Innovation – JJDC, Inc.
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
